Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First Line Durvalumab in Advanced NSCLC With Performance Status 2
NCT03620669Phase 2Active, not recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Dec 2018
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03620669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620669.